| Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449) |
|---|
| 03/15/2006 | EP1633380A2 Antimicrobial and anticancer lipopeptides |
| 03/15/2006 | EP1633372A2 Vaccines, immunotherapeutics and methods for using the same |
| 03/15/2006 | EP1633367A2 Antiangiogenic agents |
| 03/15/2006 | EP1633362A2 Compounds, methods and pharmaceutical compositions for inhibiting parp |
| 03/15/2006 | EP1633354A2 N-(((((1,3-thiazol-2-yl)amino)carbonyl)phenyl)sulfonyl)phenylalanine derivatives and related compounds for the treatment of diabetes |
| 03/15/2006 | EP1633350A2 Acylated amino acid amidyl pyrazoles and related compounds |
| 03/15/2006 | EP1633344A2 Methods and materials for treating, detecting, and reducing the risk of developing alzheimer's disease |
| 03/15/2006 | EP1633342A2 Pharmaceutical composition based on ketorolac or one of its salts pharmaceutically acceptable and use of ketorolac or its salts in pharmaceutical compositions |
| 03/15/2006 | EP1633341A2 Methods for the selective treatment of tumors by calcium-mediated induction of apoptosis |
| 03/15/2006 | EP1633340A2 Compounds for the treatment of metabolic disorders |
| 03/15/2006 | EP1633336A2 Immunosuppressant compounds and compositions |
| 03/15/2006 | EP1633323A2 Ternary and quaternary eutectic mixtures |
| 03/15/2006 | EP1633321A2 Method for purifying virus |
| 03/15/2006 | EP1633317A2 Synthetic chemokine receptor ligands and methods of use thereof |
| 03/15/2006 | EP1633316A2 Antibodies that immunospecifically bind to trail receptors |
| 03/15/2006 | EP1633315A2 Novel immunomodulating peptide |
| 03/15/2006 | EP1633311A2 Compositions and methods for modulating s-nitrosoglutathione reductase |
| 03/15/2006 | EP1633310A2 Thiotungstate analogues and uses thereof |
| 03/15/2006 | EP1633309A2 Method of inhibiting tumor growth with anti-tissue factor antibodies |
| 03/15/2006 | EP1633308A2 Hiv-1 envelope glycoproteins having unusual disulfide structure |
| 03/15/2006 | EP1633307A2 Modulation of survivin expression |
| 03/15/2006 | EP1633306A2 Use of phosphatase inhibitors as adjunct therapy for psychiatric disorders |
| 03/15/2006 | EP1633305A2 Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs with an extended therapeutic window |
| 03/15/2006 | EP1633302A2 Modulation of apolipoprotein (a) expression |
| 03/15/2006 | EP1633189A2 Truncated fragments of alpha-synuclein in lewy body disease |
| 03/15/2006 | EP1590004A4 Improved thickened beverages for dysphagia |
| 03/15/2006 | EP1465864B1 Inhibitors of factor xa and other serine proteases involved in the coagulation cascade |
| 03/15/2006 | EP1448566B1 Chemokine receptor antagonists and methods of use thereof |
| 03/15/2006 | EP1324749B1 Medicinal aerosol formulations |
| 03/15/2006 | CN1748143A Transgenic mice expressing human cd20 and/or cd16 |
| 03/15/2006 | CN1747969A Immunoglobulin variants and uses thereof |
| 03/15/2006 | CN1747965A Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
| 03/15/2006 | CN1747936A Substituted azole derivatives as therapeutic agents |
| 03/15/2006 | CN1747731A Imidazopyridines containing combinations and their use in treating gastrointestinal inflammatory disorders |
| 03/15/2006 | CN1747726A A therapeutic composition for the treatment of hiv-1 and hiv-2 |
| 03/15/2006 | CN1747703A Methods of administering a dermatological agent to a subject |
| 03/15/2006 | CN1245386C 1,2-dihydropyridine compounds, process for preparation of same and use thereof |
| 03/15/2006 | CN1245157C Novel fatty derivative for treatment of diabetes |
| 03/14/2006 | US7011818 Promotes the release of the active particles from the carrier particles on actuation of the inhaler; efficiency |
| 03/14/2006 | CA2250731C In vivo stain composition, process of manufacture, and methods of use to identify dysplastic tissue |
| 03/09/2006 | WO2006025057A1 Use of il-6 in vascular complications |
| 03/09/2006 | WO2005055925A3 14-3-3 zeta over-expression as a poor prognosis factor, and a therapeutic target in multiple cancer types |
| 03/09/2006 | WO2005040228A3 Disintegratable films for diagnostic devices |
| 03/09/2006 | WO2005027853A3 Method for treating snoring and sleep apnea with leukotriene antagonists |
| 03/09/2006 | WO2005018548A3 Building element for constructing a modular substructure |
| 03/09/2006 | WO2005018541A3 Cox-2 inhibitor and serotonin modulator for treating cns damage |
| 03/09/2006 | WO2005009390A3 Regulation of limbic system of the brain by neuro-coded signals |
| 03/09/2006 | WO2004089296A3 Improved inhibitors for the soluble epoxide hydrolase |
| 03/09/2006 | WO2004071446A3 Immune complexes |
| 03/09/2006 | US20060052617 Continuous process for the production of optically pure (s)-beta-hydroxy-y-butyrolactone |
| 03/09/2006 | US20060052471 Initiators and crosslinkable polymeric materials |
| 03/09/2006 | US20060052312 Paclitaxel hybrid derivatives |
| 03/09/2006 | US20060052270 Solid dispersion compositions |
| 03/09/2006 | US20060051821 Methods and kits for use in the diagnosis and treatment of endotoxemia |
| 03/09/2006 | US20060051361 Vaccine against Streptococcus pneumoniae |
| 03/09/2006 | US20060051333 AAV virions with decreased immunoreactivity and uses therefor |
| 03/09/2006 | US20060051296 Thickened beverages for dysphagia |
| 03/09/2006 | DE19681616B4 Prozeß zur Gewinnung von Oestrogenen aus Stutenharn Process for the production of estrogens from Stutenharn |
| 03/09/2006 | CA2579012A1 Use of il-6 in vascular complications |
| 03/08/2006 | EP1632470A2 Calcium receptor active molecules |
| 03/08/2006 | EP1632248A1 Anti-interleukin-9 antibody or anti-interleukin-9 receptor antibody for treating bronchial hyper-responsiveness |
| 03/08/2006 | EP1631597A2 Displaceable linker solid phase chemical ligation |
| 03/08/2006 | EP1631581A2 Sdr proteins from staphylococcus capitis and their use in preventing and treating infections |
| 03/08/2006 | EP1631559A2 Il-8 receptor antagonists |
| 03/08/2006 | EP1631548A2 Inhibitors of akt activity |
| 03/08/2006 | EP1631309A2 Protein kinase c peptides for use in withdrawal |
| 03/08/2006 | EP1631308A2 Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins |
| 03/08/2006 | EP1631297A2 Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents |
| 03/08/2006 | EP1631290A2 Combination therapy for the treatment of neoplasms |
| 03/08/2006 | EP1631289A2 Anti-hiv benzamide compounds |
| 03/08/2006 | EP1631279A2 Combination therapy for the treatment of neoplasms |
| 03/08/2006 | EP1631274A2 Combination of an nmda receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders |
| 03/08/2006 | EP1631272A2 Methods of treating obesity and related disorders using tellurium and selenium compounds |
| 03/08/2006 | EP1631271A2 Methods and compositions for delivery of catecholic butanes for treatment of tumors |
| 03/08/2006 | EP1631270A2 Methods and compositions for delivery of catecholic butanes for treatment of diseases |
| 03/08/2006 | EP1631269A2 Methods and compositions for delivery of catecholic butanes for treatment of obesity |
| 03/08/2006 | EP1631267A2 Method for treating diseases using hsp90-inhibiting agents in combination with antimetabolites |
| 03/08/2006 | EP1631243A2 Sexual hygienic composition |
| 03/08/2006 | EP1631239A2 Pharmaceutical compositions comprising active vitamin d compounds |
| 03/08/2006 | EP1631237A2 Proteoglycan degrading mutants for treatment of cns |
| 03/08/2006 | EP1631236A2 Cell surface protein associated with human chronic lymphocytic leukemia |
| 03/08/2006 | EP1631235A2 Compositions and methods for the modulation of the expression of b7 protein |
| 03/08/2006 | EP1631234A2 Compositions and methods for the treatment of cns injuries |
| 03/08/2006 | EP1631233A2 Methods and devices for creating electrical block at specific targeted sites in cardia tissue |
| 03/08/2006 | EP1503775B1 Formulations useful in the treatment of male and female impotence |
| 03/08/2006 | EP1404667B1 Piperidine derivatives useful as modulators of chemokine receptor activity |
| 03/08/2006 | CN1745175A Active immunization to generate antibodies to soluble A-beta |
| 03/08/2006 | CN1744913A Use of the cathelicidin LL-37 and derivatives thereof for wound healing |
| 03/08/2006 | CN1744902A Pharmaceutical combination for the treatment of cancer |
| 03/08/2006 | CN1743456A Modulators of the function of receptors of the TNF/NGF receptor family and other protein |
| 03/08/2006 | CN1743331A Process for preparing azacycloalkanoylaminothiazoles |
| 03/08/2006 | CN1743302A Arylpiperazines having 5-hydroxyl-typtamine activity |
| 03/08/2006 | CN1742731A Pyrazole-di-pyridineones for treating female sexual dysfunction |
| 03/08/2006 | CN1244813C Preparation technology of sugarless small radix bupleuri granular agent |
| 03/08/2006 | CN1244323C Novel fatty acid analogues for the treatment of primary and secondary restenosis |
| 03/07/2006 | US7008638 Use of nanodispersions in cosmetic end formulations |
| 03/02/2006 | WO2006022585A1 Composition and method for long-term glycemic control |
| 03/02/2006 | WO2005051331A3 Chaperone-based therapy for niemann-pick disease |
| 03/02/2006 | WO2005048947A3 Oral delivery system and method for making same |
| 03/02/2006 | WO2005048941A3 Novel substituted oxy-nitriles |